Destiny Pharma PLC teams up with US Department of Veterans Affairs to find ‘new attributes’ for its next-generation antibiotic
NTCD-M3 is remaining created to fight Clostridioides difficile bacterial infections (CDI) in the gut ()
NTCD-M3 is remaining created to fight Clostridioides difficile bacterial infections (CDI) in the gut ()